Compare Novo Nordisk A/S (NVO) vs Tesla, Inc. (TSLA) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Novo Nordisk A/S vs Tesla, Inc. — how do they compare? Novo Nordisk A/S trades at $38.36 (market cap $165.31B), while Tesla, Inc. trades at $383.95 (market cap $1.48T). The key difference: Tesla, Inc. is far larger — about 9× Novo Nordisk A/S's market cap, and Novo Nordisk A/S pays a 4.71% dividend while Tesla, Inc. pays none. Which is the better fit depends on your goals — on Pluang, investors hold Novo Nordisk A/S for 116 Days and Tesla, Inc. for 88 Days on average.
| NVO | TSLA | |
|---|---|---|
Market Cap | $165.31B | $1.48T |
Volume | 11,432,838 | 28,215,427 |
Sector | Health | Consumer Cyclical |
52-Week High | $63.98 | $489.88 |
52-Week Low | $35.29 | $298.16 |
Typical Hold Time | 116 Days | 88 Days |
Enterprise Value | $179.56B | $1.45T |
Dividend Yield | 4.71% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Novo Nordisk (NVO) trades at $38.26, up 1.95% today, with a bullish technical signal supported by oscillators like RSI at 20.06 (buy signal). The company shows strong fundamentals with a P/E of 9.66, net income margin of 35.35%, and consistent earnings beats in recent quarters. Recent news highlights pipeline developments, including a Wegovy pill study showing continued weight loss and a $4 billion licensing deal, though an FDA delay for a hemophilia drug poses a near-term headwind.
The outlook remains positive with a consensus price target of $44.67, implying 17% upside, driven by robust profitability and growth in GLP-1 therapies. Risks include competitive pressure from Eli Lilly, regulatory delays, and reliance on obesity/diabetes drugs. Analyst sentiment is bullish (59% buy ratings), but investors should monitor execution amid high expectations.
Tesla trades at $382.89, up 1.4% with a bullish technical signal from moving averages. The company shows mixed fundamentals with declining profit margins (3.67% net income margin) despite recent earnings beats, while valuation ratios remain elevated (P/E 347). Recent news highlights regulatory approval for driver-assistance software in Europe and a potential cheaper EV model, though Q2 2026 earnings missed expectations. Cash flow trends show consistent operational strength but heavy investment outflows.
Tesla's outlook balances innovation leadership in autonomy and energy against near-term execution risks and rich valuations. The consensus price target of $441 suggests 15% upside, but investors face volatility from competitive pressures and reliance on future technology adoption. The stock's performance hinges on delivering growth beyond traditional automotive segments.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Novo Nordisk A/S
With almost 50% market share by volume of the global insulin market, Novo Nordisk is the leading provider of diabetes-care products in the world. Based in Denmark, the company manufactures and markets a variety of human and modern insulins, injectable diabetes treatments, and oral antidiabetic agents. Novo also has a biopharmaceutical segment (constituting roughly 15% of revenue) that specializes in protein therapies for hemophilia and other disorders.
Read more on NVO →About Tesla, Inc.
Tesla Inc. designs, manufactures, and sells high-performance electric vehicles and electric vehicle powertrain components. The Company owns its sales and service network and sells electric power train components to other automobile manufacturers. Tesla serves customers worldwide.
Read more on TSLA →
